Tag
A cohort study demonstrates that reduced-dose 60-Gy chemoradiotherapy effectively maintains locoregional control in HPV-positive oropharyngeal cancer patients while minimizing treatment toxicity, with 5-year survival rates exceeding 92%.
This study identifies clinicopathologic factors linked to pre- and postoperative levels of circulating tumor HPV DNA (ctHPVDNA) in HPV-mediated oropharyngeal cancer patients treated with upfront surgery, offering insights for disease monito
This phase 3 trial shows that de-escalated adjuvant radiotherapy reduces chronic grade 3+ toxicities compared to standard chemoradiotherapy in HPV-associated oropharyngeal cancer, potentially improving patient quality of life without compro
